Coriell Life Sciences Presents ‘Science in Action’ at APHA 2019 Genomics Forum
Program implementation and evaluation data translates into medication safety and big savings
Join Coriell Life Sciences at APHA 2019, the annual meeting and expo of the American Public Health Association, where the company will present its latest precision public health findings at the Genomics Forum on November 5 at 10:30 a.m. The APHA Annual Meeting, one of the nation’s most influential public health events, will be held November 2-6 in Philadelphia, PA.
Victoria Clements, MPH, Coriell Life Sciences’ director of operations, will present outcomes from an implemented public health program in “Evaluating the benefits of a pharmacogenomics-guided medication therapy management program in a Medicare-eligible population (abstract #4098),” a collaborative initiative between Coriell Life Sciences and a public pension fund that serves more than 36,000 retirees aged 65 and older.
“I am thrilled to join others who recognize and advocate the benefits of integrating genomics into public health systems,” said Ms. Clements. “It’s extremely gratifying to be part of a team that drives real-world change and enhances outcomes at the population level.”
Clements, the lead author, will discuss how Coriell Life Sciences launched Enterprise PGx, the company’s comprehensive, patient-centered medication risk management program that integrates genetic testing with several other factors to offer a comprehensive, patient-centered approach.
The program, which combines pharmacogenomics testing with traditional Medication Therapy Management, successfully improved member health, clinicians, and saved healthcare dollars.
Once DNA analysis was completed, pharmacists reviewed each members’ medication regimen and used Coriell Life Sciences’ real-time modeling software to create custom Medication Action Plans (MAPs). The MAPs were used to communicate clear, concise, and clinically actionable information to the members’ healthcare providers.
Within the first six months, the program yielded significant cost-to-plan savings, an improvement in member health and quality of life, and a decrease in medical events associated with medication mismanagement. The one-time DNA analysis continues to serve members as they are prescribed new medications throughout their lives; they can consult with the program pharmacists to ensure any new drugs they may be prescribed are safe and effective for them.